Biognosys NULISA Proteomics Assay Services

Biognosys this week announced the commercial availability of NULISA proteomics assays for biomarker discovery in plasma and other biofluids. NULISA is a highly sensitive proteomics platform developed by Alamar Biosciences and provided by Biognosys under a strategic partnership announced last year. From its Zurich, Switzerland facility, Biognosys offers Alamar's NULISAseq CNS Disease 120 and Inflammation 250 panels, which are run on the ARGO HT System with the possibility of GCP-compliant and GLP-like lab operation services, enabling exploratory profiling of clinical trial samples. NULISAseq panels are expertly curated to enable multiplexed analysis of previously hard-to-measure cytokines, chemokines, and important disease-specific neurodegeneration markers such as pTau217. The service requires only 10 µl of plasma or other biofluids, Biognosys said.